NASDAQ:GMDA

Gamida Cell - GMDA Stock Forecast, Price & News

$3.23

0.00 (0.00%)

(As of 08/16/2022 02:15 PM ET)

Add

Compare

Today's Range: $3.06
▼
$3.25
50-Day Range: $1.53
▼
$3.39
52-Week Range: $1.48
▼
$5.59

Volume: 18,418 shs
Average Volume: 903,423 shs
Market Capitalization: $191.22 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.17

Gamida Cell MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 346.9% Upside
$14.17 Price Target
Short Interest: Bearish
5.69% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.59
Based on 14 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.22) to ($1.05) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.90 out of 5 stars

Medical Sector

870th out of 1,124 stocks

Biological Products, Except Diagnostic Industry

137th out of 176 stocks

3.5

Analyst's Opinion

Consensus Rating
Gamida Cell has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.17, Gamida Cell has a forecasted upside of 346.9% from its current price of $3.17.
Amount of Analyst Coverage
Gamida Cell has only been the subject of 1 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
5.69% of the float of Gamida Cell has been sold short.
Short Interest Ratio / Days to Cover
Gamida Cell has a short interest ratio ("days to cover") of 6.8.
Change versus previous month
Short interest in Gamida Cell has recently decreased by 4.78%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Gamida Cell does not currently pay a dividend.
Dividend Growth
Gamida Cell does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for GMDA.

2.6

News and Social Media Coverage

News Sentiment
Gamida Cell has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 14 news articles for Gamida Cell this week, compared to 2 articles on an average week.
Search Interest
35 people have searched for GMDA on MarketBeat in the last 30 days. This is an increase of 218% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Gamida Cell to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Gamida Cell insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 2.60% of the stock of Gamida Cell is held by insiders.
Percentage Held by Institutions
47.12% of the stock of Gamida Cell is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Gamida Cell are expected to grow in the coming year, from ($1.22) to ($1.05) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Gamida Cell is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Gamida Cell is -2.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Gamida Cell has a P/B Ratio of 4.28. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Gamida Cell (NASDAQ:GMDA) Stock

Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.

Gamida Cell Price Performance

GMDA Stock opened at $3.23 on Tuesday. The business has a 50 day moving average price of $1.98 and a 200 day moving average price of $2.78. The company has a quick ratio of 3.55, a current ratio of 3.55 and a debt-to-equity ratio of 2.87. The stock has a market cap of $191.22 million, a price-to-earnings ratio of -2.26 and a beta of 1.72. Gamida Cell has a fifty-two week low of $1.48 and a fifty-two week high of $5.59.

Gamida Cell (NASDAQ:GMDA - Get Rating) last issued its quarterly earnings data on Monday, August 15th. The company reported ($0.31) earnings per share for the quarter, hitting the consensus estimate of ($0.31). During the same quarter in the previous year, the company posted ($0.42) EPS. Equities research analysts anticipate that Gamida Cell will post -1.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. JMP Securities reiterated a "buy" rating and issued a $17.00 target price on shares of Gamida Cell in a report on Thursday, June 2nd. Piper Sandler raised their target price on shares of Gamida Cell from $6.00 to $8.00 in a report on Monday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Gamida Cell presently has a consensus rating of "Buy" and an average price target of $14.17.

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Stock News Headlines

August 15, 2022 | fool.com

Gamida Cell Ltd. (GMDA) Q2 2022 Earnings Call Transcript

August 15, 2022 | seekingalpha.com

Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2022 Results - Earnings Call Transcript

August 15, 2022 | finance.yahoo.com

Gamida Cell Reports Second Quarter 2022 Financial Results and Provides Company Update

August 15, 2022 | americanbankingnews.com

Analyzing Clarus Therapeutics (NASDAQ:CRXT) and Gamida Cell (NASDAQ:GMDA)

August 14, 2022 | americanbankingnews.com

Gamida Cell (GMDA) Set to Announce Earnings on Monday

August 10, 2022 | finance.yahoo.com

Gamida Cell Announces Dosing of First Patient in Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

August 9, 2022 | finance.yahoo.com

These 2 Penny Stocks Are Poised for a Big Rally, Says Oppenheimer

August 8, 2022 | finance.yahoo.com

Gamida Cell Announces the Date of Its Second Quarter 2022 Financial Results and Webcast

August 4, 2022 | finance.yahoo.com

How Many Gamida Cell Ltd. (NASDAQ:GMDA) Shares Do Institutions Own?

August 1, 2022 | msn.com

FDA Accepts Gamida's Filing For Stem Cell Transplant Candidate Under Priority Review

August 1, 2022 | nasdaq.com

FDA Accepts Gamida's BLA For Omidubicel With Priority Review

August 1, 2022 | finance.yahoo.com

Gamida Cell Announces FDA Acceptance of Biologics License Application for Omidubicel with Priority Review

July 29, 2022 | americanbankingnews.com

Gamida Cell Ltd. (NASDAQ:GMDA) Receives $13.83 Average Target Price from Analysts

June 10, 2022 | finance.yahoo.com

Gamida Cell Appoints Ivan M. Borrello, M.D., Expert in Immuno-Oncology, Cell Therapies, and Bone Marrow Transplant to Board of Directors

June 2, 2022 | seekingalpha.com

Gamida Cell completes rolling submission to the FDA for omidubicel

June 2, 2022 | finance.yahoo.com

Gamida Cell Completes Rolling Biologics License Application Submission to the FDA for Omidubicel

June 1, 2022 | finance.yahoo.com

Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference

June 1, 2022 | finance.yahoo.com

Gamida Cell Announces Opening to Enrollment of Company-Sponsored Phase 1/2 Study of NK Cell Therapy Candidate GDA-201

May 17, 2022 | finance.yahoo.com

Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference

May 10, 2022 | seekingalpha.com

Gamida Cell Ltd. (GMDA) Management on Q1 2022 Results - Earnings Call Transcript

May 10, 2022 | finance.yahoo.com

Gamida Cell Reports First Quarter 2022 Financial Results and Provides Company Update

May 9, 2022 | seekingalpha.com

Gamida Cell Q1 2022 Earnings Preview

May 5, 2022 | finance.yahoo.com

Gamida Cell Ltd. (NASDAQ:GMDA): When Will It Breakeven?

May 5, 2022 | finance.yahoo.com

Gamida Cell Presents New Data from NAM-Enabled Genetically Modified Natural Killer (NK) Pipeline at International Society for Cell & Gene Therapy 2022

May 3, 2022 | finance.yahoo.com

Gamida Cell Announces the Date of Its First Quarter 2022 Financial Results and Webcast

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive GMDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gamida Cell and its competitors with MarketBeat's FREE daily newsletter.

GMDA Company Calendar

Last Earnings: 8/15/2022
Today: 8/16/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:GMDA
CUSIP: N/A
CIK: 1600847
Web: www.gamida-cell.com
Phone: (722) 659-5666
Fax: N/A
Employees: 166
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $14.17
High Stock Price Forecast: $22.00
Low Stock Price Forecast: $8.00
Forecasted Upside/Downside: +338.6%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 6 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.43)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-89,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -205.58%
Return on Assets: -58.85%

Debt

Debt-to-Equity Ratio: 2.87
Current Ratio: 3.55
Quick Ratio: 3.55

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.74 per share
Price / Book: 4.36

Miscellaneous

Outstanding Shares: 59,200,000
Free Float: 57,661,000
Market Cap: $191.22 million
Optionable: Not Optionable
Beta: 1.72

Key Executives

Dr. Julian Adams Ph.D. (Age 67)
CEO & Director
Comp: $707k
Mr. Shai Lankry C.P.A. (Age 46)
M.B.A., Chief Financial Officer
Comp: $564k
Ms. Michele Ilene Korfin M.B.A. (Age 50)
R.Ph., Chief Operating & Chief Commercial Officer
Comp: $510k
Dr. Ronit Simantov M.D. (Age 57)
Chief Medical & Chief Scientific Officer
Comp: $581k
Dr. Jas Uppal (Age 54)
Chief Regulatory & Quality Officer
Comp: $476k
Mr. Joshua F. Patterson (Age 46)
Gen. Counsel & Chief Compliance Officer
Mr. Paul Nee
VP of Marketing
Mr. Naftali Brikashvili CPA
Sr. VP Fin. & Operations
Dr. Tracey Lodie Ph.D. (Age 52)
Scientific Advisor & Consultant
Mr. Vladimir Melnikov
Sr. VP of Global Operations & Manufacturing

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

GMDA Stock - Frequently Asked Questions

Should I buy or sell Gamida Cell stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gamida Cell in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" GMDA shares.
View GMDA analyst ratings or view top-rated stocks.
What is Gamida Cell's stock price forecast for 2022?: 6 Wall Street research analysts have issued twelve-month target prices for Gamida Cell's stock. Their GMDA share price forecasts range from $8.00 to $22.00. On average, they anticipate the company's share price to reach $14.17 in the next twelve months. This suggests a possible upside of 338.6% from the stock's current price.
View analysts price targets for GMDA or view top-rated stocks among Wall Street analysts.
How have GMDA shares performed in 2022?: Gamida Cell's stock was trading at $2.54 at the start of the year. Since then, GMDA shares have increased by 27.2% and is now trading at $3.23.
View the best growth stocks for 2022 here.
How were Gamida Cell's earnings last quarter?: Gamida Cell Ltd. (NASDAQ:GMDA) issued its quarterly earnings data on Monday, August, 15th. The company reported ($0.31) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.31). During the same quarter in the previous year, the business earned ($0.42) EPS.
What other stocks do shareholders of Gamida Cell own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Gamida Cell investors own include Matinas BioPharma (MTNB), Bionano Genomics (BNGO), Gran Tierra Energy (GTE), ADMA Biologics (ADMA), Pennsylvania Real Estate Investment Trust (PEI), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB), Enerplus (ERF) and Novan (NOVN).
When did Gamida Cell IPO?: (GMDA) raised $50 million in an IPO on Friday, October 26th 2018. The company issued 3,600,000 shares at a price of $13.00-$15.00 per share. BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO and Needham & Company Oppenheimer & Co. was co-manager.

What is Gamida Cell's stock symbol?: Gamida Cell trades on the NASDAQ under the ticker symbol "GMDA."
Who are Gamida Cell's major shareholders?: Gamida Cell's stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (7.82%), ARK Investment Management LLC (1.21%), JPMorgan Chase & Co. (0.89%), Walleye Capital LLC (0.30%), OLD National Bancorp IN (0.05%) and Cubist Systematic Strategies LLC (0.04%).
How do I buy shares of Gamida Cell?: Shares of GMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Gamida Cell's stock price today?: One share of GMDA stock can currently be purchased for approximately $3.23.
How much money does Gamida Cell make?: Gamida Cell (NASDAQ:GMDA) has a market capitalization of $191.22 million. The company earns $-89,790,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.
How many employees does Gamida Cell have?: The company employs 166 workers across the globe.
How can I contact Gamida Cell?: Gamida Cell's mailing address is 5 NAHUM HAFZADI STREET GIVAAT SHAUL, JERUSALEM L3, 91340. The official website for the company is www.gamida-cell.com. The company can be reached via phone at (722) 659-5666 or via email at irpr@gamida-cell.com.

This page (NASDAQ:GMDA) was last updated on 8/16/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Gamida Cell - GMDA Stock Forecast, Price & News

Gamida Cell MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month